Non-curative resection for surgical T4b esophageal cancer: esophagectomy or non-esophagectomy?

Langenbecks Arch Surg. 2023 May 20;408(1):201. doi: 10.1007/s00423-023-02940-2.

Abstract

Background: Recently, with the development of multidisciplinary treatment, the treatment outcomes of esophageal cancer (EC) have improved. However, despite advances in diagnostic imaging modalities, preoperative diagnosis of T4 EC is still difficult, and the prognosis of T4 EC remains very poor. In addition, the prognosis of surgical T4b EC (sT4b EC) after surgery remains unclear. In this study, we retrospectively reviewed sT4b EC.

Methods: We evaluated the clinical course of sT4b EC and compared palliative esophagectomy with R2 resection (PE group) with other procedures without esophagectomy (NE group) (e.g., only esophagostomy) for sT4b EC.

Results: Forty-seven patients with thoracic EC underwent R2 resection at our institution between January 2009 and December 2020. Thirty-four patients were in the PE group, and 13 patients were in the NE group. The 2-year overall survival rate was 0% in the PE group and 20.2% in the NE group (p = 0.882). There was one case of long-term survival in the NE group that underwent surgery followed by definitive chemoradiation. Postoperative complications (Clavien-Dindo grade ≥ 3) were observed in 25 patients (73.5%) in the PE group and in three patients (23.1%) in the NE group (p = 0.031). The median time to the initiation of postoperative treatment was 68.1 days in the PE group and 18.6 days in the NE group (p = 0191).

Conclusions: If EC is diagnosed as sT4b, palliative esophagectomy should be avoided because of the high complication rate and the lack of long-term survival.

Keywords: Chemotherapy; Esophageal cancer; Esophagectomy; R2 resection; Radiotherapy.

MeSH terms

  • Carcinoma, Squamous Cell* / surgery
  • Esophageal Neoplasms* / surgery
  • Humans
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome